TELA TELA Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TELA

Price (delayed)

$4.72

Market cap

$116.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.04

Enterprise value

$109.87M

TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is ...

Highlights
TELA Bio's gross profit has increased by 48% YoY and by 9% from the previous quarter
TELA's revenue is up by 41% year-on-year and by 10% since the previous quarter
The equity has declined by 38% since the previous quarter but it has grown by 32% year-on-year
The quick ratio is down by 23% since the previous quarter and by 15% year-on-year
The company's net income fell by 7% QoQ and by 5% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.telabio.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of TELA
Market
Shares outstanding
24.65M
Market cap
$116.35M
Enterprise value
$109.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.12
Price to sales (P/S)
1.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.88
Earnings
Revenue
$58.45M
EBIT
-$41.44M
EBITDA
-$40.63M
Free cash flow
-$41.46M
Per share
EPS
-$2.04
Free cash flow per share
-$1.81
Book value per share
$0.77
Revenue per share
$2.56
TBVPS
$3.32
Balance sheet
Total assets
$78.05M
Total liabilities
$59.17M
Debt
$40.52M
Equity
$18.88M
Working capital
$54.76M
Liquidity
Debt to equity
2.15
Current ratio
4.23
Quick ratio
3.34
Net debt/EBITDA
0.16
Margins
EBITDA margin
-69.5%
Gross margin
68.6%
Net margin
-79.8%
Operating margin
-75.4%
Efficiency
Return on assets
-58.6%
Return on equity
-201.6%
Return on invested capital
-78.8%
Return on capital employed
-67.8%
Return on sales
-70.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TELA stock price

How has the TELA Bio stock price performed over time
Intraday
1.94%
1 week
6.07%
1 month
-10.94%
1 year
-50.32%
YTD
-28.7%
QTD
-16.75%

Financial performance

How have TELA Bio's revenue and profit performed over time
Revenue
$58.45M
Gross profit
$40.11M
Operating income
-$44.08M
Net income
-$46.66M
Gross margin
68.6%
Net margin
-79.8%
TELA Bio's gross profit has increased by 48% YoY and by 9% from the previous quarter
TELA's revenue is up by 41% year-on-year and by 10% since the previous quarter
TELA Bio's net margin has increased by 25% YoY and by 3.2% from the previous quarter
The operating margin has grown by 20% YoY and by 3% from the previous quarter

Growth

What is TELA Bio's growth rate over time

Valuation

What is TELA Bio stock price valuation
P/E
N/A
P/B
6.12
P/S
1.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.88
TELA Bio's EPS has increased by 25% YoY
The P/B is 72% less than the last 4 quarters average of 21.6 and 43% less than the 5-year quarterly average of 10.7
The equity has declined by 38% since the previous quarter but it has grown by 32% year-on-year
TELA's price to sales (P/S) is 71% less than its 5-year quarterly average of 6.3 and 53% less than its last 4 quarters average of 3.9
TELA's revenue is up by 41% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is TELA Bio business performance
TELA Bio's return on equity has increased by 48% YoY
TELA Bio's ROS has increased by 27% YoY and by 2.7% from the previous quarter
TELA's ROA is up by 16% year-on-year but it is down by 3.2% since the previous quarter
TELA's ROIC is up by 9% YoY but it is down by 6% QoQ

Dividends

What is TELA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TELA.

Financial health

How did TELA Bio financials performed over time
TELA's total assets is 32% more than its total liabilities
The quick ratio is down by 23% since the previous quarter and by 15% year-on-year
The current ratio has contracted by 21% from the previous quarter and by 16% YoY
TELA Bio's debt is 115% more than its equity
TELA Bio's debt to equity has surged by 63% QoQ but it has decreased by 23% YoY
The equity has declined by 38% since the previous quarter but it has grown by 32% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.